PepTcell appoints Manfred Scheske as CEO of Consumer Health

13-Oct-2010 - United Kingdom

PepTcell, a drug discovery group with an innovative mid- to late stage portfolio, announced the appointment of Manfred Scheske as Chief Executive Officer of Consumer Health.

Scheske, former President of Consumer Healthcare Europe at GlaxoSmithKline, is joining the Executive Team at PepTcell having enjoyed a highly successful 25-year career with GSK in Europe, North America and at a global level within GSK’s Consumer Healthcare Leadership Team.

Scheske, who was President of GSK’s £2 billion strong European Consumer Healthcare business from 2004 to 2010, also spent six years as President of GSK’s Consumer Healthcare business in North America. Amongst his successes was the launch of alli, GSK’s weight loss drug, which was the first pan-European switch from Rx to OTC. He built a market-leading position in the OTC smoking cessation market in the US and played a key role in the acquisition of Block Drug.

In his newly formed role at PepTcell, Scheske will have full responsibility for the consumer health portfolio. The leading products include a first-in-class cough suppressant with a clinically proven efficacy and safety profile. In addition, within the portfolio is a small molecule drug for inflammatory flare with a clinically proven safety analgesic profile entering Phase III trials.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing

Genetic mutations that lead to macular degeneration blindness mapped by new research

Genetic mutations that lead to macular degeneration blindness mapped by new research

Barroso Commission recognises contribution of biotech crops to European competitiveness

BioVaria Start-up Awards go to ISD Immunotech and Mindpax.me

Alnylam Announces Manufacturing Agreement with Dowpharma(TM) for RNAi Therapeutics

Atugen AG raises EUR 5 million venture funding for siRNA therapeutics program - siRNA therapeutics patent application published

Vantia Therapeutics’ lead candidate VA106483 enters Phase IIb trial for nocturia

Organon and Schering to continue research in male fertility control separately

A human enzyme (CD 39) targets the Achilles heel of sepsis - New research suggests that CD39 significantly improves survival of mice in severe sepsis

Borean Pharma Acquires Proteopharma and Promising Arterial Drug

Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research - Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million

Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform